Axsome Therapeutics, Inc. $AXSM Holdings Trimmed by Integrity Alliance LLC.

Integrity Alliance LLC. trimmed its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 48.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,625 shares of the company’s stock after selling 4,358 shares during the quarter. Integrity Alliance LLC.’s holdings in Axsome Therapeutics were worth $853,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AXSM. BlackRock Inc. acquired a new position in shares of Axsome Therapeutics during the second quarter worth $759,695,000. Hillsdale Investment Management Inc. purchased a new position in Axsome Therapeutics in the first quarter worth about $9,019,000. OneDigital Investment Advisors LLC bought a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at $1,906,000. Baird Financial Group Inc. purchased a new stake in shares of Axsome Therapeutics in the second quarter worth about $2,497,000. Finally, Lisanti Capital Growth LLC purchased a new stake in shares of Axsome Therapeutics in the second quarter worth approximately $5,097,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have weighed in on AXSM. Robert W. Baird reduced their price objective on shares of Axsome Therapeutics from $246.00 to $220.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Friday, September 25th. Royal Bank Of Canada reduced their price target on shares of Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating for the company in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Thursday, October 15th. Finally, Morgan Stanley raised their price objective on shares of Axsome Therapeutics from $247.00 to $249.00 and gave the stock an “equal weight” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $267.58.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares in the company, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 20.60% of the stock is currently owned by insiders.

Axsome Therapeutics Stock Performance

Shares of Axsome Therapeutics stock opened at $132.37 on Friday. The company’s 50 day moving average price is $177.62 and its 200-day moving average price is $197.87. Axsome Therapeutics, Inc. has a 52-week low of $123.00 and a 52-week high of $260.19. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.38. The company had revenue of $259.69 million during the quarter, compared to analysts’ expectations of $249.19 million. Axsome Therapeutics had a negative return on equity of 218.52% and a negative net margin of 18.18%. Axsome Therapeutics’s revenue for the quarter was up 51.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.94) earnings per share. On average, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.57 EPS for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.